Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-26042
Läubli, H; Borsig, L (2009). Heparins attenuate cancer metastasis: are selectins the link? Cancer Investigation, 27(5):474-481.
Heparin is often used to prevent or treat thromboembolism in cancer patients. Clinical and experimental evidence suggest that heparin also has anti-cancer activities. Experimental evidence consistently supports the ability of heparin to attenuate metastasis. The potential anti-metastatic effects of heparin include the inhibition of cell-cell interactions or heparanase and modulation of growth factors and anticoagulant activity. Heparin inhibits selectin-mediated interactions of tumor cells with leukocytes, platelets and endothelial cells, which are likely to mediate the initial steps of hematogenous metastasis. Prospective clinical trials can be designed based on the insights obtained from experimental studies.
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > Institute of Physiology
07 Faculty of Science > Institute of Physiology
|DDC:||570 Life sciences; biology|
|Deposited On:||19 Jan 2010 15:24|
|Last Modified:||09 Jul 2012 04:04|
|Additional Information:||This is an electronic version of an article published in Cancer Investigation. 2009 Jun;27(5):474-81. Cancer Investigation is available online at http://informahealthcare.com/doi/abs/10.1080/07357900802647136|
Scopus®. Citation Count: 9
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page